



## Association Studies in Clinical Pharmacogenetics—Volume II

Guest Editors:

**Prof. Dr. Francisco Abad Santos**

Princesa Multidisciplinary Initiative for the Implementation of Pharmacogenetics (PriME-PGx), Clinical Pharmacology Department, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, 28006 Madrid, Spain

**Dr. Pablo Zubiaur**

Princesa Multidisciplinary Initiative for the Implementation of Pharmacogenetics (PriME-PGx), Clinical Pharmacology Department, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, 28006 Madrid, Spain

Deadline for manuscript submissions:

**closed (24 April 2024)**

### Message from the Guest Editors

Dear Colleagues,

The progress of Clinical Pharmacogenetics has been remarkable. Its implementation in the United States and Europe is gradually increasing. At the regulatory level, agencies such as the American Food and Drug Administration (FDA) or the European Medicines Agency (EMA) already incorporate genotyping indications in drug labels. In addition, other consortia such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) or the Dutch Pharmacogenetics Working Group (DPWG) or national societies such as the Spanish Society of Pharmacogenetics and Pharmacogenomics (SEFF) develop pharmacogenetic clinical guidelines with prescribing recommendations based on patient's genotype. The drafting of such guidelines depends on the generation of pharmacogenetic evidence, which is collected and, eventually, associations with a high level of evidence are established that may require a dose adjustment or drug change.

The aim is to compile sound works from any field of pharmacology that will increase the pharmacogenetic knowledge of drugs without previous clinical validation. Papers that generate new and previously unpublished evidence will also be considered.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

---

Pharmaceutics Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma